Men's-Health Telehealth Pivot to GLP-1
Hims & Hers, Ro, and the Compounded-Semaglutide Boom and Bust
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Branded GLP-1s approved; compounded versions were never FDA-approved
Reference only. Not medical advice.
What can go wrong
Compounded GLP-1 products were never FDA-approved; potency, purity, and dosing accuracy varied, and the FDA warned of dosing errors and adverse events. Telehealth prescribing of weight-loss drugs has drawn scrutiny over the adequacy of medical evaluation, the appropriateness of 'corporate practice of medicine' arrangements, and continuity of monitoring. Patients who relied on compounded supply faced abrupt transitions and price changes when the shortage resolved.
This is something to take to a clinician. The Atlas can tell you what is known about men's-health telehealth pivot to glp-1 in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Direct-to-consumer telehealth platforms that built their brands on erectile dysfunction and hair loss (Hims & Hers, Ro) pivoted aggressively into GLP-1 weight loss, which became a major revenue engine. During the 2024-2025 FDA shortage of branded semaglutide and tirzepatide, these platforms sold compounded versions at cash prices. When the FDA declared the shortages resolved in 2025, the legal basis for mass compounding collapsed, triggering a rapid and contentious business-model shift toward branded drugs and microdosing offerings.
How weight loss became the growth engine of men's telehealth.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
The legal and regulatory collision
Compounding under sections 503A/503B is normally permitted when a drug is on the FDA shortage list. Telehealth platforms scaled compounded semaglutide and tirzepatide during the 2024-2025 shortage. Once the FDA declared the shortages resolved, that pathway closed, and manufacturers escalated. Eli Lilly sued multiple telehealth firms (April 2025), in part advancing 'corporate practice of medicine' theories, and pursued compounders, clinics, and med-spas over Mounjaro/Zepbound. Novo Nordisk filed its first US patent-infringement suit against Hims & Hers (February 2026) over a compounded oral semaglutide pill. The boom-and-bust arc is central to understanding the current marketplace.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Eli Lilly / Novo Nordisk
Compounded GLP-1 knockoffs may be dangerous and unapproved; the manufacturers pursued litigation against telehealth firms and compounders after the shortage resolved.
Set against the alternatives
Versus traditional in-clinic obesity care, the telehealth GLP-1 model trades physician continuity for speed, cash-price convenience, and asynchronous refills. During the 2024 shortage, compounded semaglutide let platforms undercut branded list prices, but that advantage was regulatory, not clinical, and it evaporated once the FDA declared the shortage resolved in 2025. The surviving differentiation is now distribution and adherence tooling rather than price: branded-drug access (via manufacturer channels such as NovoCare and LillyDirect), 'microdosing' programs that stretch supply, and bundled coaching. Compared with manufacturer-direct programs, the independent platforms offer broader cross-category bundling (ED, hair, mental health) but face litigation and supply dependence on the very drugmakers they compete with.
| Platform | GLP-1 model | Era | Note |
|---|---|---|---|
| Hims & Hers | Compounded, then branded + microdose | 2024 boom, 2025-26 pivot | Largest weight-loss revenue line |
| Ro | Compounded, then branded access | 2024 boom, 2025 shift | Branded Wegovy/Zepbound partner deals |
| Branded-only telehealth | NovoCare / LillyDirect referral | 2025 onward | Manufacturer-aligned cash channels |
| Gray-market sellers | Compounded combos / peptides | Post-shortage | Higher regulatory and safety risk |
GLP-1 weight loss transformed men's-health telehealth economics. Hims & Hers projected roughly $725M in 2025 weight-loss revenue; in FY2024 its compounded GLP-1 offerings alone generated about $225M (~16% of Online Revenue). The model leveraged subscription DTC infrastructure originally built for ED and hair loss. When shortages resolved, platforms reported losses on the transition (Hims posted a Q1 loss in 2026 as it shifted to branded GLP-1) and pivoted to microdosing and branded fulfillment to preserve the revenue stream.
What we do not know
- Will manufacturer-direct cash channels (NovoCare, LillyDirect) erode independent telehealth margins on branded GLP-1?
- Are 'microdosing' programs clinically justified or primarily a supply and price workaround?
- How durable is weight-loss revenue once patients reach goal weight and discontinue?
- What share of compounded-era patients can transition to branded therapy without dropping off?
- How will permanent post-pandemic telehealth and compounding rules reshape the legal model?
What could change
Oral GLP-1 accessPill-based orforglipron and oral semaglutide could simplify telehealth fulfillmentManufacturer-direct competitionNovoCare and LillyDirect cash programs pressure independent platformsMicrodosing programsLower-dose maintenance offerings marketed amid supply and cost constraintsLitigation overhangNovo Nordisk actions against compounding-linked telehealth reshape the segmentMaintenance and off-ramp modelsFocus shifting from rapid loss to long-term weight maintenance subscriptions
At a glance
- Hims & Hers 2025 weight-loss revenue guidance
- ~$725M projected
- Compounded GLP-1 share (Hims FY2024)
- ~$225M, ~16% of Online Revenue
- Pivot
- From compounded to branded GLP-1 + 'microdosing' programs (2025-2026)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Men's-Health Telehealth Pivot to GLP-1. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- Children and teenagers. We have not checked what is known about younger people.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.